Ablative therapy with UGN-102 for low-grade intermediate risk non-muscle-invasive bladder cancer: ready for primetime?

Lichtbroun, Benjamin; Ghodoussipour, Saum; Packiam, Vignesh T

Lichtbroun, Benjamin; Ghodoussipour, Saum; Packiam, Vignesh T.

Afiliação

Lichtbroun B; Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
Ghodoussipour S; Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.
Packiam VT; Section of Urologic Oncology, Division of Urology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.

Transl Androl Urol ; 13(4): 647-649, 2024 Apr 30.

Article em En | MEDLINE | ID: mdl-38721287

Palavras-chave

Non-muscle-invasive bladder cancer (NMIBC); ablative therapy; mitomycin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Transl Androl Urol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos